©2024 Stanford Medicine
Intralesional Cemiplimab for Adult Patients With Cutaneous Squamous Cell Carcinoma or Basal Cell Carcinoma
Not Recruiting
Trial ID: NCT03889912
Purpose
This study is researching an experimental drug called cemiplimab. The study is focused on
Cutaneous Squamous Cell Carcinoma (CSCC) and Basal Cell Carcinoma (BCC).
The aim of the study is to evaluate the safety and tolerability (how your body reacts to the
drug) of cemiplimab (also known as REGN2810).
The first part of the study tested several different doses of cemiplimab given weekly for 12
weeks.
The study is also looking at several other research questions, including:
- What side effects may happen from taking the study drug
- To see effect of cemiplimab on the tumor
- How much study drug is in the blood at different times
Official Title
A Phase 1 Study of Pre-Operative Cemiplimab (REGN2810), Administered Intralesionally, for Patients With Cutaneous Squamous Cell Carcinoma (CSCC) or Basal Cell Carcinoma (BCC)
Stanford Investigator(s)
Anne Lynn S. Chang, MD
Professor of Dermatology
Eligibility
Key Inclusion Criteria
1. Dose Escalation: History of recurrent resectable CSCC or BCC (Cohort C and I only)
that satisfies conditions as defined in the protocol
2. Patients must have measurable disease in the index lesion, defined as 1-2 cm in the
longest diameter
3. Eastern Cooperative Oncology Group (ECOG) performance status ≤1
Key Exclusion Criteria
1. Ongoing or recent (within 5 years) evidence of significant autoimmune disease that
required treatment with systemic immunosuppressive treatments, which may suggest risk
for immune-mediated adverse events (imAEs)
2. Prior treatment with an agent that blocks the programmed cell death 1 (PD-1)/
programmed cell death 1 ligand (PD-L1) pathway.
3. Prior treatment with other systemic immune modulating agent as defined in the protocol
4. M1 or N1, N2 (a, b, or c), or N3 CSCC or BCC. Patients with history of metastatic CSCC
(distant or nodal), or metastatic BCC (distant or nodal) are excluded unless the
disease-free interval is at least 3 years
5. Concurrent malignancies, other than those with negligible risk of metastasis or death.
Patients with hematologic malignancies, including chronic lymphocytic leukemia (CLL),
are excluded.
6. Patients with a history of solid organ transplant
7. Has received a Coronavirus induced disease of 2019 (COVID-19) vaccination (initial
series and booster) within 1 week of planned start of study medication
Note: Other protocol defined Inclusion/Exclusion criteria apply.
Intervention(s):
drug: Cemiplimab
Not Recruiting
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Alexander Ayon Valencia
650-498-5185